Mirum Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Product Sales: Approximately $160 million for Q1 2026, up from $112 million in Q1 2025.

Cash Position: Cash, cash equivalents, and investments totaled $421 million as of March 31, 2026, compared to $391 million at the beginning of the year.

Operating Expenses: Total operating expenses were $949 million, largely impacted by a $761 million expense related to the acquisition of Bluejay Therapeutics.

Cash Flow: Cash flow from operations was approximately $2 million, with a cash contribution margin from commercial business in the mid-50% range.

Guidance: Full-year revenue guidance raised to $660 million to $680 million, reflecting strong demand for Libmarli, particularly in PFIC.

2Strategic Updates and Business Highlights

Product Portfolio: Mirum has expanded from a single product focus on Libmarli to a broader portfolio with three approved medicines and a pipeline targeting rare liver and genetic diseases.

Libmarli Performance: Strong uptake in PFIC, especially among adult patients, with continued education efforts driving awareness.

New Developments:

Positive clinical readouts for elixirat in PSC and berlivatig in hepatitis delta, with upcoming presentations at EASL.

Acquisition of zolergosertib for FOP, with an NDA accepted and a PDUFA date set for September 26, 2026.

Commercial Expansion: Plans to expand the U.S. field commercial team from 20 to 60 personnel to enhance outreach to liver healthcare providers.

3Forward Guidance and Outlook

Revenue Expectations: The company anticipates continued growth in net product sales, particularly from Libmarli, and expects to be operating cash flow positive in 2027.

R&D Investments: Increased R&D spending anticipated in 2026 to support the development of berlivatig and zolergosertib, with a focus on maintaining financial independence.

4Challenges and Points of Concern

High Operating Expenses: The significant increase in operating expenses due to the Bluejay acquisition raises concerns about short-term profitability.

Market Competition: The entry of competitive therapies, particularly in the FOP space, may impact market share and pricing strategies.

Patient Identification: Challenges remain in identifying FOP patients due to high misdiagnosis rates and the need for increased awareness among healthcare providers.

5Notable Q&A Insights

FOP Patient Estimates: Approximately 300 diagnosed FOP patients in the U.S., with the majority expected to be treatable at launch.

Libmarli Sales Drivers: The guidance increase is primarily driven by strong performance in the U.S. PFIC market, with adult patients being a key growth segment.

Zolergosertib Differentiation: The oral formulation of zolergosertib is seen as a significant advantage over existing injectable therapies, with expectations for a strong clinical profile.

Regulatory Strategy: The company is actively pursuing an ex-U.S. filing for zolergosertib, with a European filing expected soon. Overall, Mirum Pharmaceuticals is positioned for growth with a robust pipeline and strategic initiatives, despite facing challenges related to competition and high operating costs.